ACSL4/FACL4 Antibody | Affinity Biosciences

$Figure S3 ORMDL3 overexpression decreases ER-mito distance and promotes NLRP3 localization to mitochondria not total NLRP3 expression.A, human MDMs were transfected with scrambled or siORMDL3 for 24 h, treated with LPS (200 ng/ml) along with MSU nigericin (10 μM) for 6 h. Summary graph showing western blot densitometry analysis of NLRP3 localization to mitochondria and total NLRP3 level in total cell lysates from 4 donors. B, subcellular fractions including ER, Mitochondria, and MAM were isolated from HeLa cells and assessed for purity of ER, mitochondria and MAM fractions by Western blotting using antibodies against FACL4 (MAM marker) or calnexin (ER marker), or VDAC (mitochondrial marker). C, HeLa cells were transfected with myc tagged ORMDL3 full length plasmid or Empty vector (Ev) for 24 h and assessed for ORMDL3 overexpression efficiency in total cell lysate by western blotting using myc antibody, GAPDH was used as loading control. D, ER-mito contact distance quantified after acquiring images by transmission electron microscopy(TEM) (A total of 20 cells were quantified for ER-mito contact distance in Ev and myc-ORMDL3 transfected cells). Mean ± SEM; ∗∗P < 0.01; ∗∗∗∗P < 0.0001 as determined by one-way ANOVA for Figure 2A and two-way ANOVA for Figure 2D. ns denotes non-significant.$

ACSL4/FACL4 Antibody - Figure S3 ORMDL3 overexpression decreases ER-mito distance and promotes NLRP3 localization to mitochondria not total NLRP3 expression.

ACSL4/FACL4 Antibody - Figure 8.

ACSL4/FACL4 Antibody - Fig.

ACSL4/FACL4 Antibody - Figure 3.

ACSL4/FACL4 Antibody - Figure 6.

ACSL4/FACL4 Antibody - Figure 7.

ACSL4/FACL4 Antibody - Fig.

ACSL4/FACL4 Antibody - FIGURE 6 Effects of the ARNTL expression in AML cancer cell lines in vitro.

Product:	ACSL4/FACL4 Antibody
Catalog:	DF12141
Description:	Rabbit polyclonal antibody to ACSL4/FACL4
Application:	WB IHC IF/ICC
Cited expt.:	WB, IHC, IF/ICC
Reactivity:	Human, Mouse, Rat
Prediction:	Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.:	79 kDa,74 kDa; 79kD(Calculated).
Uniprot:	O60488
RRID:	AB_2844946

View similar products>>

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific.

Size	Price	Inventory
100ul	$280	In stock
200ul	$350	In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Related Downloads

MS Report

HPLC Report

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Source:

Rabbit

Application:

WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:

Human,Mouse,Rat

Prediction:

Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(83%)

Clonality:

Polyclonal

Specificity:

ACSL4/FACL4 Antibody detects endogenous levels of total ACSL4/FACL4.

RRID:

AB_2844946
Cite Format: Affinity Biosciences Cat# DF12141, RRID:AB_2844946.

Conjugate:

Unconjugated.

Purification:

The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

Storage:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Alias:

Fold/Unfold

ACS 4; ACS4; ACSL 4; Acsl4; ACSL4_HUMAN; acyl CoA synthetase 4; Acyl CoA synthetase long chain family member 4; FACL 4; FACL4; Fatty acid Coenzyme A ligase; fatty acid Coenzyme A ligase long-chain 4; LACS 4; LACS4; Lignoceroyl CoA synthase; Long chain 4; long chain acyl CoA synthetase 4; long chain fatty acid CoA ligase 4; long chain fatty acid Coenzyme A ligase 4; Long-chain acyl-CoA synthetase 4; Long-chain-fatty-acid--CoA ligase 4; MRX63; MRX68;

Immunogens

Immunogen:

A synthesized peptide derived from human ACSL4/FACL4, corresponding to a region within N-terminal amino acids.

Uniprot:

O60488(ACSL4_HUMAN) >>Visit HPA database.

Gene(ID):

ACSL4(2182)

Sequence:

O60488 ACSL4_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MKLKLNVLTIILLPVHLLITIYSALIFIPWYFLTNAKKKNAMAKRIKAKPTSDKPGSPYRSVTHFDSLAVIDIPGADTLDKLFDHAVSKFGKKDSLGTREILSEENEMQPNGKVFKKLILGNYKWMNYLEVNRRVNNFGSGLTALGLKPKNTIAIFCETRAEWMIAAQTCFKYNFPLVTLYATLGKEAVVHGLNESEASYLITSVELLESKLKTALLDISCVKHIIYVDNKAINKAEYPEGFEIHSMQSVEELGSNPENLGIPPSRPTPSDMAIVMYTSGSTGRPKGVMMHHSNLIAGMTGQCERIPGLGPKDTYIGYLPLAHVLELTAEISCFTYGCRIGYSSPLTLSDQSSKIKKGSKGDCTVLKPTLMAAVPEIMDRIYKNVMSKVQEMNYIQKTLFKIGYDYKLEQIKKGYDAPLCNLLLFKKVKALLGGNVRMMLSGGAPLSPQTHRFMNVCFCCPIGQGYGLTESCGAGTVTEVTDYTTGRVGAPLICCEIKLKDWQEGGYTINDKPNPRGEIVIGGQNISMGYFKNEEKTAEDYSVDENGQRWFCTGDIGEFHPDGCLQIIDRKKDLVKLQAGEYVSLGKVEAALKNCPLIDNICAFAKSDQSYVISFVVPNQKRLTLLAQQKGVEGTWVDICNNPAMEAEILKEIREAANAMKLERFEIPIKVRLSPEPWTPETGLVTDAFKLKRKELRNHYLKDIERMYGGK

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species

Results

Score

Pig

100

Horse

100

Bovine

100

Sheep

100

Dog

100

Chicken

100

Rabbit

100

Xenopus

Zebrafish

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

O60488_ACSL4_HUMAN

Function:

Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoA for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially activates arachidonate and eicosapentaenoate as substrates. Preferentially activates 8,9-EET > 14,15-EET > 5,6-EET > 11,12-EET. Modulates glucose-stimulated insulin secretion by regulating the levels of unesterified EETs (By similarity). Modulates prostaglandin E2 secretion.

Subcellular Location:

Mitochondrion outer membrane>Single-pass type III membrane protein. Peroxisome membrane>Single-pass type III membrane protein. Microsome membrane>Single-pass type III membrane protein. Endoplasmic reticulum membrane>Single-pass type III membrane protein. Cell membrane.

Family&Domains:

Belongs to the ATP-dependent AMP-binding enzyme family.

Research Fields

· Cellular Processes > Transport and catabolism > Peroxisome. (View pathway)

· Cellular Processes > Cell growth and death > Ferroptosis. (View pathway)

· Metabolism > Lipid metabolism > Fatty acid biosynthesis.

· Metabolism > Lipid metabolism > Fatty acid degradation.

· Metabolism > Global and overview maps > Metabolic pathways.

· Metabolism > Global and overview maps > Fatty acid metabolism.

· Organismal Systems > Endocrine system > PPAR signaling pathway.

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

References

1). Glycolysis-Derived Lactate Induces ACSL4 Expression and Lactylation to Activate Ferroptosis during Intervertebral Disc Degeneration. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025 (PubMed: 40171826) [IF=15.1]

2). Identification and analysis of microplastic aggregation in CAR-T cells. Journal of hazardous materials, 2024 (PubMed: 39488976) [IF=13.6]

3). Sonocatalytic Eradication of Hepatocellular Carcinoma by Tailoring Structural Defects of Black Indium Oxide Sonocatalysts and Leveraging Apoptosis/Ferroptosis-Hybridized Pathways. Small (Weinheim an der Bergstrasse, Germany), 2026 (PubMed: 41627202) [IF=13.0]

4). Time-restricted feeding protects against septic liver injury by reshaping gut microbiota and metabolite 3-hydroxybutyrate. Gut microbes, 2025 (PubMed: 40223164) [IF=12.2]

Application: IF/ICC Species: Mouse Sample: liver tissue

Figure 6. 3-HB inhibits ferroptosis in mice by activating the PI3K/AKT/mTOR/LPIN1 pathway. (a) GSEA-kegg analysis. (b) Relative mRNA levels of Acsl4, Gpx4, SLC7a11, Fth1 and hmox-1 genes, n = 5–6. (c, d) ACSL4 immunofluorescence and quantification in liver tissues, scale: 100 μm, n = 6. (e-g) MDA, LPO and Fe2+ content in liver tissue, n = 6. (h, i) ACSL4 immunofluorescence and quantification in liver tissues, scale: 100 μm, n = 6. (j) Relative ACSL4 mRNA expression level, n = 6–8. (k-m) MDA, LPO and Fe2+ content in liver tissue from mice in the CLP, CLP+NVP-BEZ235, CLP + 3-HB, and CLP + 3-HB+NVP-BEZ235 groups, n = 6. (n) ACSL4 immunofluorescence of liver tissue from WT and Lpin1KO mice, scale: 100 μm, n = 6. (o) Quantitative analysis of ACSL4 immunofluorescence intensity, n = 6. (p) Relative ACSL4 mRNA expression level, n = 6–8. (q-s) MDA, LPO and Fe2+ content in liver tissue from WT and Lpin1KO mice, n = 6. The results are expressed as the median and quartile. * p

Application: WB Species: Mouse Sample: AML12 cells

Figure 7. 3-HB alleviates AML12 cell injury by activating the PI3K/AKT/mTOR/LPIN1 pathway to inhibit ferroptosis. (a) AML12 cell viability was detected by CCk8, n = 6. (b) LDH content in AML12 cell supernatant, n = 6. (c-f) MDA, LPO, TGSH and Fe2+ content in the AML12 cells, n = 4. (g) AML12 cell viability by CCk8, n = 6. (h) LDH content in AML12 cell supernatant, n = 6. (i-k) the protein expression levels of p-akt, PI3K, p-mTOR, LPIN1 and ACSL4 in the AML12 cells treated with LPS, LPS+NVP-BEZ235, LPS + 3-HB, and LPS + 3-HB+NVP-BEZ235 (n = 3). (l-o) MDA, LPO, TGSH and Fe2+ content in the AML12 cells treated with LPS, LPS+NVP-BEZ235, LPS + 3-HB, and LPS + 3-HB+NVP-BEZ235, n = 4. (p) LPIN1 protein expression level, n = 4. (q) The protein expression levels of LPIN1 and ACSL4 in the AML12 cells (n = 3). (r) AML12 cell viability by CCk8, n = 6. (s) LDH content in AML12 cell supernatant, n = 6. (t-w) MDA, LPO, TGSH and Fe2+ content in AML12 cells transfected with Ctrl shRNA and Lpin1 shRNA, n = 4. The results are expressed as the mean ± SEM. *p < 0.05，**p

5). Interplay between lipid dysregulation and ferroptosis in chondrocytes and the targeted therapy effect of metformin on osteoarthritis. Journal of advanced research, 2025 (PubMed: 38621621) [IF=11.4]

6). The deubiquitinase USP11 ameliorates intervertebral disc degeneration by regulating oxidative stress-induced ferroptosis via deubiquitinating and stabilizing Sirt3. Redox biology, 2023 (PubMed: 37099926) [IF=10.7]

7). Dual-responsive stem cell microspheres modified with BDNF for enhanced neural repair in diabetic erectile dysfunction. Journal of controlled release : official journal of the Controlled Release Society, 2025 (PubMed: 39761859) [IF=10.5]

8). Internalized polystyrene nanoplastics trigger testicular damage and promote ferroptosis via CISD1 downregulation in mouse spermatocyte. Journal of nanobiotechnology, 2025 (PubMed: 40707955) [IF=10.2]

Application: WB Species: Mouse Sample:

Fig. 2 PS-NPs induce testicular ferroptosis in mice. (A-C) The concentration of total Fe, MDA and GSH in mice serum after PS-NPs exposure. (D-F) Effect of PS-NPs on total Fe, MDA and GSH in mice testes. (G) Gene expression of ferroptosis-associated genes in isolated testes using qRT-PCR after treatment. (H and I) Western blotting and quantitative analysis of ferroptosis-related protein expression. (J and K) Immunofluorescence images of GPX4 and SLC7A11 in testes following PS-NPs treatment for 35 days

9). EBF1-induced CSRP2 boosts the progression of B-cell acute lymphocytic leukemia by inhibiting ferroptosis. Cancer letters, 2025 (PubMed: 39952599) [IF=9.1]

10). Voluntary exercise alleviates neural functional deficits in Parkinson's disease mice by inhibiting microglial ferroptosis via SLC7A11/ALOX12 axis. NPJ Parkinson's disease, 2025 (PubMed: 40122927) [IF=8.7]

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

ACSL4/FACL4 Antibody - #DF12141